Egalet Corporation (NASDAQ:EGLT) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition.

On May10, 2017, Egalet Corporation (the Company) issued a press
release announcing its financial results for its first quarter
ended March31, 2017. A copy of that press release and the
attached financial schedules are attached as Exhibit99.1 to this
report and incorporated herein by reference.

On May 10, 2017, the Company will hold an Investor Day
presentation during which it will provide information about the
Company, including selected financial data, to investors. A copy
of that selected financial data is attached to this report as
slide 71 of Exhibit 99.2, which is incorporated herein by
reference.

The information included in this Item 2.02 (including Exhibit99.1
and slide 71 of Exhibit 99.2) is being furnished to Item 2.02 and
shall not be deemed to be filed for purposes of Section18 of the
Securities Exchange Act of 1934 (the Exchange Act) or otherwise
subject to the liabilities of that Section, nor shall it be
deemed to be incorporated by reference in any filing under the
Securities Act of 1933, as amended (the Securities Act), or the
Exchange Act.

Item 7.01 Regulation FD Disclosure

As disclosed above, on May10, 2017, the Company will hold an
Investor Day presentation during which it will provide
information to investors about the Company. Exhibit99.2 is a copy
of the slides to be used at, and posted on the Companys website
in connection with, the presentation.

The information included in this Item 7.01 (including
Exhibit99.2) is being furnished to Item 7.01 and shall not be
deemed to be filed for purposes of Section18 of the Exchange Act
or otherwise subject to the liabilities of that Section, nor
shall it be deemed to be incorporated by reference in any filing
under the Securities Act or the Exchange Act.

Cautionary Note on Forward Looking Statements

This Current Report on Form8-K (including the Exhibits 99.1 and
99.2 hereto) contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These statements are based on the current beliefs and
expectations of the Companys management and are subject to
significant risks and uncertainties. Actual results may differ
from those set forth in the forward-looking statements. Factors
that could cause the Companys actual results to differ materially
from those described in the forward-looking statements can be
found in Egalet Corporations Annual Report on Form10-K for the
year ended December31, 2016 filed with the Securities and
Exchange Commission (SEC) and in other filings that the Company
makes with the SEC from time to time. Egalet Corporation does not
undertake to update the forward-looking statements to reflect the
impact of circumstances or events that may arise after the date
of the forward-looking statements.

Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits.

About Egalet Corporation (NASDAQ:EGLT)

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company’s product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company’s product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company’s product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company’s product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.

Egalet Corporation (NASDAQ:EGLT) Recent Trading Information

Egalet Corporation (NASDAQ:EGLT) closed its last trading session up +0.20 at 3.16 with 207,676 shares trading hands.